Intervention group | Lω | LP | Pω | PP |
---|---|---|---|---|
Group description and size | L. reuteri + ω-3 PUFA n = 18 | L. reuteri + Placebo n = 16 | Placebo + ω-3 PUFA n = 15 | Placebo + Placebo n = 14 |
Female | 6/18 (33%) | 7/16 (44%) | 12/15 (80%)* | 3/14 (21%) |
Birth week | 39.5 (39.0–41.0) | 40.0 (38.8–40.2) | 40.0 (40.0–41.0) | 40.0 (39.0–41.0) |
Treatment duration | 19.0 (19.0–21.2) | 19.5 (19.0–20.0) | 20.0 (19.5–21.0) | 20.0 (19.0–20.8) |
Maternal age (birth) | 31.0 (29.0–32.8) | 32.0 (30.0–33.2) | 32.0 (29.0–33.0) | 30.0 (28.2–32.5) |
Caesarean delivery | 3/17 (18%) | 0/16 (0%) | 1/15 (7%) | 1/14 (7%) |
Birth weight (kg) | 3.8 (3.6–3.9) | 3.5 (3.3–3.9) | 3.9 (3.7–4.1) | 3.8 (3.6–4.1) |
Birth height (cm) | 51.0 (50.0–52.0) | 51.5 (49.8–52.2) | 51.0 (50.5–52.5) | 51.0 (50.0–52.0) |
Maternal atopy | 14/18 (78%) | 11/16 (69%) | 7/15 (47%) | 8/14 (57%) |
Paternal atopy | 9/18 (50%) | 9/16 (56%) | 9/15 (60%) | 11/14 (79%) |
Siblings | 1.0 (0.0–1.0) | 1.0 (0.0–1.2) | 1.0 (0.0–1.5) | 0.0 (0.0–1.0) |
People in home | 4.0 (3.0–4.0) | 4.0 (3.0–5.0) | 3.0 (3.0–4.0) | 3.5 (3.0–4.0) |
Smoking in home | 0/18 (0%) | 0/16 (0%) | 0/12 (0%) | 1/14 (7%) |
Breastfeeding (at 3 months) | 15/18 (83%) | 12/16 (75%) | 9/12 (75%) | 12/14 (86%) |
Antibiotics (during first 3 months) | 1/15 (7%) | 1/14 (7%) | 0/10 (0%) | 0/11 (0%) |
Pets in home (at 3 months) | 4/18 (22%) | 5/16 (31%) | 3/11 (27%) | 1/13 (8%) |
Naïve CD4+ CD45RA + cells (%) | 95.6 (94.6–97.4) | 96.6 (95.7–97.1) | 95.7 (95.3–97.3) | 95.9 (94.5–96.9) |
Memory CD4+ CD45RA- cells (%) | 4.4 (2.6–5.4) | 3.4 (2.9–4.3) | 4.3 (2.7–4.7) | 4.1 (3.1–5.5) |